LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Design Therapeutics Inc

Design Therapeutics Inc

Cerrado

14.36 -0.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

13.82

Máximo

14.53

Métricas clave
By Trading Economics
Ingresos	-1.6M -18M
BPA	-0.29
Empleados	54
EBITDA	-1.5M -20M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+8.83% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	175M 975M
Apertura anterior	14.91
Cierre anterior	14.36

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

3.26 / 3.63 Soporte y Resistencia

Design Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 may 2026, 16:02 UTC

Ganancias

Principales Movimientos del Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 may 2026, 14:55 UTC

Principales Movimientos del Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 may 2026, 14:43 UTC

Principales Movimientos del Mercado

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 may 2026, 17:28 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 may 2026, 16:24 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 15:55 UTC

Charlas de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 may 2026, 15:20 UTC

Ganancias

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 may 2026, 14:33 UTC

Charlas de Mercado

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparación entre iguales

Cambio de precio

Design Therapeutics Inc previsión

Precio Objetivo

By TipRanks

8.83% repunte

Estimación a 12 Meses

Media 17 USD 8.83%

Máximo 21 USD

Mínimo 14 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Design Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Design Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.26 / 3.63Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.